Anaconda Biomed closed a $56 million financing led by Omega Funds to complete its ATHENA pivotal study, advance products, and pursue regulatory approvals.
- Amount
- $56M
- Announced
- 23 September 2026
- Lead
- Omega Funds
- Other investors
- Asabys (Sabadell Asabys II), Ysios Capital, CDTI (through its SICC Innvierte)
- Use of funds
- Complete ATHENA pivotal IDE study, continue product development, and secure global regulatory approvals
- Checked
- Announced by the company